MX2023004223A - Nuevos anticuerpos anti-cd47 y usos de los mismos. - Google Patents

Nuevos anticuerpos anti-cd47 y usos de los mismos.

Info

Publication number
MX2023004223A
MX2023004223A MX2023004223A MX2023004223A MX2023004223A MX 2023004223 A MX2023004223 A MX 2023004223A MX 2023004223 A MX2023004223 A MX 2023004223A MX 2023004223 A MX2023004223 A MX 2023004223A MX 2023004223 A MX2023004223 A MX 2023004223A
Authority
MX
Mexico
Prior art keywords
antibodies
well
novel anti
hemagglutination
humans
Prior art date
Application number
MX2023004223A
Other languages
English (en)
Inventor
Wei Cao
Zhengyi Wang
Bingshi Guo
Cong Xu
Original Assignee
I Mab Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I Mab Biopharma Co Ltd filed Critical I Mab Biopharma Co Ltd
Publication of MX2023004223A publication Critical patent/MX2023004223A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

En el presente documento se proporcionan anticuerpos CD47 y fragmentos inmunológicamente activos de los mismos que tienen baja inmunogenicidad en humanos y causan un nivel bajo o nulo de depleción de glóbulos rojos o hemaglutinación. También se proporcionan composiciones farmacéuticas que contienen dichos anticuerpos o fragmentos de anticuerpo, así como métodos de tratamiento usando dichos anticuerpos, por ejemplo, como agentes únicos o en combinación con otro(s) agente(s) terapéutico(s).
MX2023004223A 2020-10-14 2021-10-14 Nuevos anticuerpos anti-cd47 y usos de los mismos. MX2023004223A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020120869 2020-10-14
CN2020122188 2020-10-20
PCT/CN2021/123892 WO2022078465A1 (en) 2020-10-14 2021-10-14 Novel anti-cd47 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2023004223A true MX2023004223A (es) 2023-08-03

Family

ID=81207683

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004223A MX2023004223A (es) 2020-10-14 2021-10-14 Nuevos anticuerpos anti-cd47 y usos de los mismos.

Country Status (12)

Country Link
US (1) US20230399400A1 (es)
EP (1) EP4229088A1 (es)
JP (1) JP2023546277A (es)
KR (1) KR20230114745A (es)
CN (1) CN116348601A (es)
AU (1) AU2021360633A1 (es)
CA (1) CA3198895A1 (es)
CO (1) CO2023005611A2 (es)
IL (1) IL302112A (es)
MX (1) MX2023004223A (es)
TW (1) TW202229351A (es)
WO (1) WO2022078465A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220104298A (ko) 2016-10-20 2022-07-26 아이-맵 바이오파마 유에스 리미티드 새로운 cd47 단일클론 항체 및 그 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220104298A (ko) * 2016-10-20 2022-07-26 아이-맵 바이오파마 유에스 리미티드 새로운 cd47 단일클론 항체 및 그 용도
AU2018363479B2 (en) * 2017-11-10 2021-09-16 I-Mab Biopharma Us Limited Fusion proteins containing CD47 antibodies and cytokines
KR20210098427A (ko) * 2018-10-31 2021-08-10 아이-맵 바이오파마 유에스 리미티드 신규한 ｃｄ47 항체 및 이의 사용방법
CA3097443A1 (en) * 2018-11-12 2020-05-22 I-Mab Biopharma Us Limited Fusion proteins containing cd47 antibodies and cytokines

Also Published As

Publication number Publication date
US20230399400A1 (en) 2023-12-14
IL302112A (en) 2023-06-01
EP4229088A1 (en) 2023-08-23
TW202229351A (zh) 2022-08-01
CN116348601A (zh) 2023-06-27
JP2023546277A (ja) 2023-11-01
KR20230114745A (ko) 2023-08-01
CO2023005611A2 (es) 2023-05-29
WO2022078465A1 (en) 2022-04-21
CA3198895A1 (en) 2022-04-21
AU2021360633A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
BR9912653A (pt) Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
RU2014134365A (ru) Вакцины против clostridium difficile, включающие рекомбинантные токсины
EP1362127A4 (en) SERPIN-BASED MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV INFECTION AND THE USE THEREOF
AR032743A1 (es) Composiciones y metodos para la terapia y el diagnostico de cancer de pulmon
NO20041844L (no) Peptider som er effektive i behandlingen av tumorer og andre tilstander i forbindelse med fjerning eller odeleggelse av celler
WO2003061578A3 (en) Compositions for treatment or prevention of bioterrorism
DE60331933D1 (de) Benutzung von alpha (1,3) -galactosyltransferase exprimierenden allogenen tumorzellen zur impfung gegen tumoren
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
DE602004018788D1 (de) Faktor-ixa-spezifische antikörper, die faktor-viiia-ähnliche wirkung zeigen
MX2022015734A (es) Proteinas de exotoxina a modificadas.
NO20082098L (no) Formuleringer av AICA-ribosid
MX2023004223A (es) Nuevos anticuerpos anti-cd47 y usos de los mismos.
Krone et al. The biography of the immune system and the control of cancer: from St Peregrine to contemporary vaccination strategies
BR112022008371A2 (pt) Anticorpos anti-cd45 e conjugados dos mesmos
WO2005067460A3 (en) Epha2 vaccines
HUP0400840A2 (hu) Kis molekulatömegű hialuronsav immunogén készítményei, és eljárások A. csoportbeli és C. csoportbeli Streptococcusok által okozott fertőzések és betegségek megelőzéséhez, kezeléséhez és diagnózisához
ATE473756T1 (de) Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs
WO2021257695A8 (en) Methods and compositions related to neutralizing antibodies against human coronavirus
BR0111024A (pt) Composições e métodos para a terapia e diagnóstico de câncer de mama
AR029540A1 (es) COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
MXPA04007491A (es) Tratamiento profilactico y terapeutico de infecciones y otras enfermedades con compuestos inmunoefectores.
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
HK1117035A1 (en) Methods of applying ionization radiation for therapy of hiv infection
WO2000063386A3 (en) Prevention, diagnosis and treatment of lyme disease